EMA

Many stakeholders have already commented on the EU?s incentives for pediatric drug development.

The European Union is working to develop pediatric rules to ensure that medicines prescribed for children are safe, effective, and of high quality.

EU proposals are finally available for the pharmaceutical industry to begin commenting on, and you can bet the industry will take advantage of it.

With the impending expansion of the EU and the revamping of current policies, the pharmaceutical industry is on edge, wanting to know what the future holds.

Facing an immediate future of rapid growth, the EU is looking to clarify its clinical trials policies, but it?s having some problems.

To help protect patient safety and cut red tape, the European Union is working to create tougher standards of pharmacovigilance.

European Parliament debates on the allocation of research funds reveals Euro-MPs views of clinical research in medicines development.

A high-level group explores ways to support EU pharmaceutical industry research without too much cost to the EU health agencies that pay for medicines.

Patients, research companies, and regulatory authorities may all benefit from proposed changes to current pharmaceutical legislation, but the proposals will provoke much debate.

EU regulators try to stay a step ahead of the pharmaceutical industry, and the industry keeps a wary eye on Europe's evolving regulatory environment.